会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • METALLOPROTEINASE INHIBITORS
    • 金属蛋白酶抑制剂
    • WO1998023588A1
    • 1998-06-04
    • PCT/GB1997003258
    • 1997-11-27
    • BRITISH BIOTECH PHARMACEUTICALS LIMITEDFLOYD, Christopher, David
    • BRITISH BIOTECH PHARMACEUTICALS LIMITED
    • C07D209/48
    • C07K5/06078A61K38/00C07K5/0606
    • Compounds of formula (I) wherein R2 is a group -(Alk)m-(Q)n-(Alk )p-Ar wherein m, n and p are independently 0 or 1, Alk and Alk each independently represents a divalent (C1-C3)alkylene group, Q represents -O-, -S-, -SO-, or -SO2-, and Ar represents an optionally substituted phenyl or heteroaryl group; R1 is hydrogen or acyl; R21 is a group -(CH2)t-W wherein t represents 1, 2, 3 or 4 and W represents a 5- or 6-membered N-heterocyclic ring as defined in the specification; Z is either (a) a saturated 5- to 8-membered monocyclic or bridged N-heterocyclic ring as defined in the specification, or (b) a radical of formula (IB) wherein R3 is the side chain of a natural or non-natural alpha -amino acid in which any functional groups may be protected; R4 is one of a variety of groups defined in the specification; and R5 is hydrogen or a (C1-C6)alkyl group. The compounds are matrix metalloproteinase inhibitors.
    • 其中R2是基团 - (Alk)m-(Q)n-(Alk 1)p-Ar的式(I)化合物其中m,n和p各自独立地为0或1,Alk和Alk 1各自独立地为 独立地表示二价(C1-C3)亚烷基,Q表示-O - , - S-,-SO-或-SO2-,Ar表示任选取代的苯基或杂芳基; R1是氢或酰基; R 21是基团 - (CH 2)t-W,其中t表示1,2,3或4,W表示说明书中定义的5-或6-元N-杂环; Z是(a)如说明书中定义的饱和的5-至8-元单环或桥连的N-杂环,或(b)式(IB)的基团,其中R 3是天然或非 - 任何官能团可被保护的天然α-氨基酸; R4是规范中定义的各种组之一; 并且R 5是氢或(C 1 -C 6)烷基。 这些化合物是基质金属蛋白酶抑制剂。
    • 10. 发明申请
    • N-(AMINO ACID) SUBSTITUTED SUCCINIC ACID AMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS
    • 作为金属蛋白酶抑制剂的N-(氨基酸)取代的磺酸酰胺衍生物
    • WO1997003966A1
    • 1997-02-06
    • PCT/GB1995001698
    • 1995-07-19
    • BRITISH BIOTECH PHARMACEUTICALS LIMITEDBECKETT, Paul, RaymondWHITTAKER, MarkMILLER, AndrewMARTIN, Fionna, Mitchell
    • BRITISH BIOTECH PHARMACEUTICALS LIMITED
    • C07D213/75
    • C07D213/75C07C259/06C07C323/60
    • Compounds selected from the group consisting of 2,N -dihydroxy-3-isobutyl-N -[2-methoxy-2-methyl-1-(pyridin-2-yl-carbamoyl)-propyl]-succinamide, N -(2-fluoro-2-methyl-1-methylcarbamoyl-propyl)-N -hydroxy-2-isobutyl-3-methoxy-succinamide, N -hydroxy-2-isobutyl-N -(2-mercapto-2-methyl-1-methylcarbamoyl-propyl)-3RS-methoxy-succinamide, 2-allyl-N -(2-fluoro-2-methyl-1-methylcarbamoyl-propyl)-N -hydroxy-3-isobutyl-succinamide, 2-allyl-N -hydroxy-3-isobutyl-N -(2-methyl-1-methylcarbamoyl-2-phenyl-propyl)-succinamide, 2-allyl-N -(2,2-dimethyl-1-methylcarbamoyl-but-3-enyl)-N -hydroxy-3-isobutyl-succinamide, 3-(3-hydroxycarbamoyl-2-isobutyl-hex-5-enoylamino)-2,2,N-trimethyl-succinamic acid methyl ester, 3-[2,2-dimethyl-1-(pyridin-2-ylcarbamoyl)-propylcarbamoyl]-2-hydroxy-5-methyl-hexanoic acid, and salts hydrates or solvates thereof, are matrix metalloproteinase inhibitors and inhibitors of the release of TNF-alpha.
    • 选自2,N 1 - 二羟基-3-异丁基-N 4 - [2-甲氧基-2-甲基-1-(吡啶-2-基 - 氨基甲酰基) - 丙基] - 琥珀酰胺的化合物 N 2 - (2-氟-2-甲基-1-甲基氨基甲酰基 - 丙基)-N 4 - 羟基-2-异丁基-3-甲氧基 - 琥珀酰胺,N 4 - 羟基-2-异丁基 - N 1 - (2-巯基-2-甲基-1-甲基氨基甲酰基 - 丙基)-3RS-甲氧基 - 琥珀酰胺,2-烯丙基-N 4 - (2-氟-2-甲基-1-甲基氨基甲酰基 - 丙基 )-N 1 - 羟基-3-异丁基 - 琥珀酰胺,2-烯丙基-N 1 - 羟基-3-异丁基-N 4 - (2-甲基-1-甲基氨基甲酰基-2-苯基 - 丙基) - 琥珀酰胺,2-烯丙基-N 4 - (2,2-二甲基-1-甲基氨基甲酰基 - 丁-3-烯基)-N 1 - 羟基-3-异丁基 - 琥珀酰胺,3-(3-羟基氨基甲酰基 - 2-异丁基 - 己-5-烯酰基氨基)-2,2,N-三甲基 - 琥珀酰胺酸甲酯,3- [2,2-二甲基-1-(吡啶-2-基氨基甲酰基) - 丙基氨基甲酰基] -2-羟基 - 5-甲基己酸及其盐的水合物或溶剂合物是基质金属蛋白酶抑制剂和TNF-α释放抑制剂。